title stringlengths 1 1.19k | keywords stringlengths 0 668 | concept stringlengths 0 909 | paragraph stringlengths 0 61.8k | PMID stringlengths 10 11 |
|---|---|---|---|---|
Keywords | Open access funding provided by The Science, Technology & Innovation Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank (EKB). | PMC10007824 | ||
Introduction | infected instrumentation debris, periodontitis, necrotic | APICAL PERIODONTITIS, PERIODONTITIS, NECROTIC | The ultimate goal of root canal therapy is to prevent apical periodontitis or to allow healing of an existing-apical periodontitis by rendering the root canal system as free as possible from microorganisms. This is accomplished by disinfecting the whole root canal system through meticulous shaping and irrigation [Most ... | PMC10007824 |
Methodology | PMC10007824 | |||
Study design | 3.1.9.2, calculus | All procedures performed were carried out in accordance with relevant guidelines, regulations and ethical standards of the ethical committee of research of the Faculty of Dentistry, Suez Canal University (approval number for the study: 137/2018.)This study was a single-blinded study, conducted on 60 human mandibular fi... | PMC10007824 | |
Samples preparation | CM, WL | A #10 K-file (Dentsply-Maillefer, Ballaigues, Switzerland) was inserted into the root canals until it was visible under the DOM at the apical foramen to ensure the canal is patent. Length was taken, and 1 mm was subtracted to determine the established working length (WL). A glide path was established. The coronal openi... | PMC10007824 | |
Samples grouping | Sections were reassembled and divided into 3 groups according to the activation method. Samples were blindly and equally distributed among the groups. | PMC10007824 | ||
Group 1 (NA) | agitation, WL | 1 mL 5.25% NaOCl was introduced into each root canal and left inserted 1 mm short of the WL in each canal and left without agitation for 30 s. | PMC10007824 | |
Group 2 (Irrisafe) | 1 mL 5.25% NaOCl was introduced into each root canal and an Irrisafe tip (of a size 20/0.00 taper and length of 21 mm (IRR20)) was inserted to 1 mm from the working length, and activated for 30 s at a medium power setting using NSK Varios 370. | PMC10007824 | ||
Group 3 (EDDY) | 1 mL 5.25% NaOCl was introduced into each root canal for 30 s and an EDDY tip of a size (25/0.04 taper) attached to the airscaler (AS2000, NSK, Nakanishi, Tochigi-ken, Japan) was inserted to 1 mm from the working length to activate the irrigant for 30 s with 2 mm up & down amplitude in each root canal.In all groups, ir... | PMC10007824 | ||
Statistical analyses | Statistical analyses were done using the computer software SPSS for Mac OS version 26.0 (Statistical package for social Science, Armonk, NY, IBM Corp) at a significance level of 0.05. According to the Shapiro–Wilk normality test data were parametric ( | PMC10007824 | ||
Results | PMC10007824 | |||
Intragroup comparison | Comparisons between mean percentage of isthmus cleanliness before and after different activation techniques (comparison within the same group): The mean of isthmus cleanliness (%) changed significantly from i1 (after chemomechanical preparation) to i2 (after final irrigation) at all measured levels (2 mm, 4 mm, and 6 m... | PMC10007824 | ||
Discussion | tooth | ENLARGEMENT | The fundamental goal of root canal therapy is disinfection of the root canal system followed by proper coronal and apical sealing, while the role of shaping is to remove infected dentin and provide space for irrigant penetration and subsequent obturation. Irrigation during shaping does not eliminate half of the debris ... | PMC10007824 |
Acknowledgements | Not applicable. | PMC10007824 | ||
Authors’ contributions | The first author run the experiment and wrote the main manuscript text. The second and third authors prepared the study design,figures and revised the whole manuscript. All authors contributed significantly to this study and have read and approved the submission of this manuscript to your journal for publication. | PMC10007824 | ||
Funding | Open access funding provided by The Science, Technology & Innovation Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank (EKB). No financial support was granted for this study from any external source. | PMC10007824 | ||
Availability of data materials | This data made available on reasonable request to the corresponding author. Also,This research article is available as a preprint on research square ( | PMC10007824 | ||
Declarations | PMC10007824 | |||
Ethics approval and consent to participate | All procedures performed were carried out in accordance with relevant guidelines, regulations and approved by the ethical committee of research of the Faculty of Dentistry, Suez Canal University (approval number for the study: 137/2018.) and all patients agreed on using their extracted teeth in research with a informed... | PMC10007824 | ||
Consent for publication | Not applicable. | PMC10007824 | ||
Competing interests | The authors deny any conflicts of interest related to this study. | PMC10007824 | ||
References | PMC10007824 | |||
Background | cancer | CANCER, CHRONIC DISEASES | Chemotherapy is associated with a wide range of physical and psychological side effects, so complementary and alternative therapies may be practiced as an independent treatment or combined with the standard ones to improve health-related quality of life of cancer patients. Laughter yoga has predominantly been used as a... | PMC10259013 |
Methods | cancer, Cancer | ONCOLOGY, CANCER, CANCER | This study was a two-group randomized clinical trial on 69 cancer patients undergoing chemotherapy at Reza Radiotherapy and Oncology Center, Iran in 2018. Patients were randomly divided into intervention and control groups. The intervention group received laughter yoga for four sessions at one-week intervals. Each sess... | PMC10259013 |
Results | sleep disturbance, fatigue, pain | ADVERSE EVENTS, DISEASE | The number of participants in intervention and control groups were 34 and 35, there was no significant difference of demographic and disease related characteristics and pre-intervention HRQOL between two groups. In the intervention group, there is significant difference between pre- and post-intervention scores (Mean ±... | PMC10259013 |
Conclusions | cancer | CANCER | A structured laughter yoga intervention in a hospital setting effectively improved health-related quality of life for cancer patients undergoing chemotherapy. Benefits to many patients could be expected if this would become a part of routine care. | PMC10259013 |
Trial Registration | This study was registered in the Iranian Registry of Clinical Trials (no. IRCT20180429039463N1) on 21/08/2018. | PMC10259013 | ||
Supplementary Information | The online version contains supplementary material available at 10.1186/s12906-023-04028-2. | PMC10259013 | ||
Keywords | PMC10259013 | |||
Introduction | cancer, deaths, humor, Cancer | CANCER, CARDIOVASCULAR DISEASES, CANCER | Cancer accounts for 9% of all deaths across the world, and the second leading cause of mortality in developing nations following cardiovascular diseases [Laughter yoga is a type of complementary therapy which also incorporates some other components including mild type of physical exercises. This type of treatment combi... | PMC10259013 |
Methods | PMC10259013 | |||
O trial design | cancer | CANCER | This study was a single-center, two-group randomized clinical trial comparing the effects of structured laughter yoga program in cancer patients before chemotherapy. The study is reported using the CONSORT (Consolidated Standards of Reporting Trials) checklist. | PMC10259013 |
O participants | cancers, stomatitis, cancer, thrombocytopenia, upper gastrointestinal (UGI) cancer | CANCERS, STOMATITIS, CANCER, DISEASE, THROMBOCYTOPENIA, ONCOLOGY | The inclusion criteria were cancer patients with an age range of 18–60, having non-metastatic type of cancers, no auditory-visual problems, undergoing four sessions of chemotherapy per month, absence of stomatitis symptoms, no upper gastrointestinal (UGI) cancer, attending no simultaneous radiotherapy programs, as well... | PMC10259013 |
O intervention | cancer, Cancer | CANCER, CANCER | The intervention group received laughter yoga for four sessions with one-week intervals. Each session lasts for 20–30 min and it consists of 15 steps of laughter yoga performed consecutively. And each laugh lasts approximately 30 to 45 s. This intervention was provided by researchers who had completed laughter yoga tra... | PMC10259013 |
O outcomes | shortness of breath, nausea/vomiting, sleep disturbance, fatigue, diarrhea, cancer, pain, constipation, Cancer | APPETITE LOSS, CANCER, CANCER | The primary outcome of this trial was HRQOL, which was assessed using EORTC QLQ-C30 (European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire version 3). Demographic information was also collected using a structured questionnaire.Demographic information questionnaire had 6 questions ... | PMC10259013 |
O sample size and randomization | cancer | CANCER, BLIND | The sample size was determined by 34 patients in each group based on the results of a pilot study on 10 participants in each group using the comparison of two means formula with 95% confidence interval and 80% test power. Assuming the possibility of participants being lost to follow up loss of some cases, and to give m... | PMC10259013 |
O statistical methods | cancer | CANCER | The data was analyzed using the SPSS Statistics (v.20) software total of 69 cancer patients out of 78 were included in the data analysis as nine cancer patients were lost to follow -up. Questionnaire was checked for completeness just after the participants returned it. The descriptive statistics (viz., frequency distri... | PMC10259013 |
Results | dyspnea, diarrhea, fatigue, appetite, constipation, pain | DISEASE, RECRUITMENT | 390 patients were assessed for eligibility. Once the desired sample size was reached, recruitment efforts ended. The 78 eligible candidates were randomly allocated into intervention (n = 39) and control (n = 39). The final number of participants available for comparison of baseline and flow up data was 69. The number o... | PMC10259013 |
Discussion | rheumatoid arthritis, sleep disturbance, fatigue, breast cancer, cancer, pain, increases pain | RHEUMATOID ARTHRITIS, CANCER, INFLAMMATION, BREAST CANCER | Our study shed light the effect of laughter yoga on HRQOL in cancer patients undergoing chemotherapy. The findings revealed that the implementation of the laughter yoga has improved the cancer patients HRQOL in terms of emotional functioning, role functioning, physical functioning, and overall HRQOL status. Laughter yo... | PMC10259013 |
Conclusion | cancer, sleep disturbance, fatigue, pain | CANCER | This trial showed that a structured laughter yoga intervention program in a hospital setting delivered by trained instructor for 20–30 min each week for four weeks before chemotherapy effectively improve health-related quality of life of the cancer patients undergoing chemotherapy. This intervention showed enhancement ... | PMC10259013 |
Acknowledgements | ONCOLOGY | The authors hereby extend their sincere gratitude to the heads of the Radiotherapy Center, the Oncology Center, the Psychology Center, the educational supervisor, the head nurse, and the nurses working at the Reza Radiotherapy and Oncology Center, Mashhad, Iran. | PMC10259013 | |
Authors’ contributions | MN, prepared the writing of the initial draft, acquisition of data, analyze and interpret the data, conceptualize the paper, and review and synthesize the literature. SRM, obtained funding for the manuscript, supervised, proof-read, and provided intellectual support in terms of statistical analysis and administrative, ... | PMC10259013 | ||
Funding | This study was a part of Master’s Thesis in Medical-Surgical Nursing with project code no. 970132. To carry out this study, Dr. Seyyed Reza Mazlum obtained a fund by the Vice-Chancellor’s Office for Research at Mashhad University of Medical Sciences, Mashhad, Iran. | PMC10259013 | ||
Data Availability | The datasets generated in the present study are available from the corresponding author upon reasonable request. | PMC10259013 | ||
Declarations | PMC10259013 | |||
Ethics approval and consent to participate | cancer | ONCOLOGY, CANCER | The research was approved by the Research Ethics Committees of Mashhad University of Medical Sciences, Mashhad, Iran (no. IR.MUMS.NURSE.REC.1397.021). The approval was gained from the Director of Reza Radiotherapy and Oncology Center managers and head nurse. Before obtaining consent, researcher approached the patients ... | PMC10259013 |
Consent for publication | Not applicable. | PMC10259013 | ||
Competing interests | The authors declare no competing interests. | PMC10259013 | ||
Abbreviations | Health-related quality of lifeUpper gastrointestinalEuropean Organization for Research and Treatment of CancerMinistry of Health and Medical EducationWorld Health OrganizationGlobal health and quality of life | PMC10259013 | ||
References | PMC10259013 | |||
Abstract | PMC10274306 | |||
Background and Aims | Ulcerative colitis, UC | DISEASE, ULCERATIVE COLITIS | Ulcerative colitis [UC] impacts patients’ health-related quality of life [HRQoL]. We assessed HRQoL and an exploratory patient-level composite endpoint (‘Comprehensive Disease Control’ [CDC]) in individuals receiving filgotinib [an oral JAK1 preferential inhibitor] in the SELECTION trial. | PMC10274306 |
Methods | UC | REMISSION, RECTAL BLEEDING | In SELECTION [NCT02914522], a double-blind, randomized, placebo-controlled, phase 2b/3 trial, adults with moderately to severely active UC received once-daily filgotinib 200 mg, filgotinib 100 mg or placebo for 11 weeks in Induction Study A [biologic-naïve] or B [biologic-experienced]. Filgotinib responders [week 10 cl... | PMC10274306 |
Results | Analyses included 382 biologic-naïve and 404 biologic-experienced patients. Filgotinib 200 mg induced and maintained improvements vs placebo in SF-36, EQ-5D, WPAI and IBDQ scores, and restored HRQoL by week 10. Proportionally more filgotinib 200 mg- than placebo-treated patients achieved CDC at weeks 10 and 58 [ | PMC10274306 | ||
Conclusions | DISEASE | Filgotinib 200 mg results in short- and long-term improvements in HRQoL. High-level improvement of HRQoL relates to a stringent composite endpoint suggesting meaningful disease control in a subset of filgotinib-treated individuals.ClinicalTrials.gov identifier: NCT02914522 | PMC10274306 | |
1. Introduction | inflammatory bowel disease of the colonic mucosa, Ulcerative colitis, UC | ULCERATIVE COLITIS | Ulcerative colitis [UC] is an inflammatory bowel disease of the colonic mucosa that negatively affects patients’ health-related quality of life [HRQoL].Patients consider the ability to improve HRQoL to be among the most important attributes of a UC treatment.Filgotinib is an oral Janus kinase [JAK] 1 preferential inhib... | PMC10274306 |
2. Materials and Methods | PMC10274306 | |||
2.1. Overall study design | SELECTION [NCT02914522] was a combined phase 2b/3 double-blind, randomized, placebo-controlled trial comprising two induction studies and a Maintenance Study. Details of the study design have been previously described by Feagan | PMC10274306 | ||
2.2. Pre-specified exploratory analyses | As part of pre-specified exploratory analyses of SELECTION, changes from induction/maintenance baseline in the following outcomes were assessed at weeks 10 and 58: generic HRQoL, as measured by SF-36 physical component summary [PCS], mental component summary [MCS] and subscale scores, as well as EQ-5D visual analogue s... | PMC10274306 | ||
2.3.
| PMC10274306 | |||
2.3.1. Achievement of MCIDs in HRQoL outcomes | presenteeism | The proportions of patients achieving the minimal clinically important difference [MCID] in the following measures at weeks 10 and 58 were assessed: SF-36 PCS score, SF-36 MCS score, EQ-5D VAS score, EQ-5D UK utility score, IBDQ total score, combined IBDQ and SF-36 scores [achievement of the MCID in each of IBDQ total ... | PMC10274306 | |
2.3.2. Restoration of SF-36-defined HRQoL | SF-36 scores relative to age–sex norms were examined. The proportions of patients with an SF-36 PCS or MCS score <40 at induction baseline who achieved restored SF-36-defined HRQoL [SF-36 PCS or MCS score ≥40] | PMC10274306 | ||
2.3.3. Assessment of individual patient treatment benefits: achievement of an exploratory composite endpoint, CDC | REMISSION, RECTAL BLEEDING | The proportion of patients who achieved CDC, comprising four established treatment outcomes, was assessed at weeks 10 and 58. Patients were considered to have achieved CDC if they achieved: (1) partial Mayo Clinic Score [pMCS] remission [pMCS ≤2 and no individual rectal bleeding, stool frequency or physician’s global a... | PMC10274306 | |
2.4. Statistical analyses | REGRESSION, REMISSION | These analyses were conducted using the SELECTION induction and maintenance full analysis sets.Patient demographics and baseline characteristics were analysed using descriptive statistics. Changes from induction baseline to week 10 and from maintenance baseline to week 58 were calculated for each HRQoL measure using le... | PMC10274306 | |
3. Results | PMC10274306 | |||
3.1. Patient disposition and baseline characteristics | INFLAMMATORY BOWEL DISEASE, DISEASE CHARACTERISTIC, ULCERATIVE COLITIS | These analyses included 382 and 404 patients from Induction Studies A and B, respectively, and 297 patients from the Maintenance Study. Patient baseline demographic and disease characteristics were similar between treatment groups within each induction study [Baseline demographics and characteristics of patients in Ind... | PMC10274306 | |
3.2. Primary HRQoL analyses | PMC10274306 | |||
3.2.1. SF-36 | INFLAMMATORY BOWEL DISEASE | At week 10, patients who had received filgotinib 200 mg had greater LS mean increases from induction baseline in SF-36 PCS and MCS scores than those who had received placebo [Proportions of patients achieving the MCID in SF-36, EQ-5D, WPAI and IBDQ total scores in Induction Studies A and B at week 10 and in the Mainten... | PMC10274306 | |
3.2.2. EQ-5D | At week 10, filgotinib 200 mg-treated patients had a greater LS mean increase from induction baseline in EQ-5D VAS and EQ-5D-5L UK utility scores than placebo-treated patients, in both the biologic-naïve and biologic-experienced populations [all At week 58, patients in the filgotinib 200 mg group experienced LS mean in... | PMC10274306 | ||
3.2.3. WPAI | Greater proportions of patients who received filgotinib 200 mg than those who received placebo achieved the MCID in WPAI activity impairment score at week 10 [biologic-naïve, | PMC10274306 | ||
3.2.4. IBDQ | REMISSION | At week 10, filgotinib 200 mg-treated patients had a greater LS mean increase from induction baseline in IBDQ total score than placebo-treated patients (biologic-naïve: 51 vs 30 points, Δ 21 [95% CI, 13, 28], At week 58, patients in the filgotinib 200 mg group experienced an LS mean increase from maintenance baseline i... | PMC10274306 | |
3.3. Secondary HRQoL analyses | PMC10274306 | |||
3.3.1. Proportions of patients achieving CDC | INFLAMMATORY BOWEL DISEASE, REMISSION, DISEASE | To assess the treatment benefits of filgotinib 200 mg in individuals, we evaluated the proportions of patients who achieved the exploratory composite endpoint, CDC [comprising pMCS remission, endoscopic improvement, inflammatory biomarker remission and IBDQ remission] at weeks 10 and 58. In the overall induction popula... | PMC10274306 | |
3.3.2. Proportions of patients experiencing minimal clinically important improvements and declines in HRQoL and work productivity measures by CDC achievement | INFLAMMATORY BOWEL DISEASE, REMISSION, DISEASE | To evaluate the association between CDC achievement and HRQoL, we assessed clinically important improvements from induction baseline to week 10, and clinically important declines from maintenance baseline to week 58, in generic HRQoL and work productivity outcomes. Greater proportions of patients who achieved CDC at we... | PMC10274306 | |
3.3.3. Proportions of patients in histological remission among CDC achievers vs non-achievers | INFLAMMATORY BOWEL DISEASE, DISEASE, REMISSION, DISEASE | To assess the relationship between achievement of CDC and histomorphology [as an objective marker of disease activity], the proportions of patients who did and did not achieve CDC who were in histological remission were investigated. At week 10, greater proportions of CDC achievers than non-achievers were in histologic... | PMC10274306 | |
4. Discussion | filgotinib, UC | DISEASE, REMISSION, DISEASE COURSE | This study assessed the effects of treatment with filgotinib on generic and disease-specific HRQoL, and work productivity in patients with UC in the SELECTION trial. Moreover, to examine the effect of filgotinib at the patient level, we developed and evaluated a four-component composite endpoint, CDC. Treatment with fi... | PMC10274306 |
4.1. Conclusions | REMISSION | Based upon data from the SELECTION trial, filgotinib 200 mg resulted in short- and long-term improvements in generic and disease-specific HRQoL. Filgotinib 200 mg led to some patients achieving a stringent exploratory composite endpoint that may be associated with both improved HRQoL and histological remission. Further... | PMC10274306 | |
Supplementary Material | Click here for additional data file. | PMC10274306 | ||
Acknowledgments | We thank Ken Hasegawa [Gilead Sciences Inc.] for his contributions to the primary data analysis. Medical writing support for the preparation of the manuscript was provided by Frances Thompson, PhD, of PharmaGenesis London, London, UK, and funded by Galapagos NV [Mechelen, Belgium]. | PMC10274306 | ||
Funding | This work (i.e. the SELECTION trial) was supported by Gilead Sciences Inc. Galapagos NV was a collaborator for the SELECTION trial and funded this analysis. | PMC10274306 | ||
Conflict of Interest | Janssen, Johnson & Johnson,, IBD | S.S. reports speaker/consultancy fees from AbbVie, Advanced Molecular Transport, Amgen, Bristol Myers Squibb [BMS], Boehringer Ingelheim, Falk, Ferring Pharmaceuticals, Galapagos/Gilead, Genentech/Roche, Janssen, Merck/MSD, Pfizer, Prometheus and Takeda. B.G.F. reports grants and personal fees from AbbVie, Amgen, Astra... | PMC10274306 | |
Author Contributions | M.F., K.H., A.O. and H.P. contributed to study design. S.S., B.G.F., L.P.B., S.V. and S.D. contributed to data collection. M.F. and P.D. contributed to data analysis. All authors contributed to data interpretation. All authors contributed to the development of the manuscript and all authors approved the final version. ... | PMC10274306 | ||
Data Availability | Colitis, Crohn’s | COLITIS | Anonymized individual patient data will be shared upon request for research purposes dependent upon the nature of the request, the merit of the proposed research, the availability of the data and its intended use. The full data sharing policy for Gilead Sciences, Inc., can be found at Part of this work was presented at... | PMC10274306 |
References | PMC10274306 | |||
Background | depression, post-traumatic stress disorder, co-occurring mental health disorders | DISORDER, DISORDERS | Identifying patients in primary care services with opioid use disorder and co-occurring mental health disorders is critical to providing treatment. Objectives of this study were to (1) assess the feasibility of recruiting people to screen in-person for opioid use disorder and co-occurring mental health disorders (depre... | PMC9881516 |
Methods | co-occurring mental health disorders | DISORDER, RECRUITMENT | This cross-sectional feasibility and pilot study recruited participants from four primary care clinics, two rural and two urban, from three health care organizations in New Mexico. Inclusion criteria were adults (≥ 18 years), attending one of the four clinics as a patient, and who spoke English or Spanish. Exclusion cr... | PMC9881516 |
Results | depression, opioid use disorder, post-traumatic stress disorder, co-occurring mental health disorders | DISORDER | Over two-weeks, 1478 potential participants were approached and 1145 were consented and screened (77.5% of patients approached). Probable opioid use disorder and co-occurring mental health disorders were identified in 2.4% of those screened compared to 0.8% in EHR. Similarly, universal screening relative to EHR identif... | PMC9881516 |
Conclusions | depression, post-traumatic stress disorder | DISORDER, DISORDERS | Universal screening for opioid use disorder, depression, and post-traumatic stress disorder was feasible, and identified three times as many patients with these co-occurring disorders compared to EHR. Higher proportions of each condition were also identified, especially post-traumatic stress disorder. Results support t... | PMC9881516 |
Supplementary Information | The online version contains supplementary material available at 10.1186/s13722-023-00362-5. | PMC9881516 | ||
Keywords | PMC9881516 | |||
Background | co-occurring mental health disorders, depression, OUD, pain, post-traumatic stress disorder, PTSD, SUDs, Depression | DISORDER, RECRUITMENT, DISORDERS | Mental health disorders often co-occur with substance use disorders (SUDs), especially opioid use disorder (OUD), and are often untreated [Depression, unhealthy drug use, and post-traumatic stress disorder (PTSD) are all common disorders in patients who receive care in PC settings [Co-occurring PTSD and OUD is common b... | PMC9881516 |
Methods | PMC9881516 | |||
Study design and setting | OUD, depressive disorder, PTSD, MDD, depression | RECRUITMENT | We administered a cross-sectional survey within four family-practice clinics from three healthcare organizations in New Mexico. Two clinics were located within the Albuquerque city limits and two were in rural areas in Central and Southwestern counties. Three of the clinics were classified as Federally Qualified Health... | PMC9881516 |
Participants and procedures | Over a two-week study period, research assistants approached people in each of the clinic waiting rooms to screen for eligibility. Adults, ages 18 and older, attending one of the four clinics as a patient, and who spoke English or Spanish were considered eligible and approached. Potential participants were told, “ | PMC9881516 | ||
Measures | depression, OUD, PTSD | ABUSE | Two sources of data were used for this study: aggregate data from each clinic’s EHR and the survey data from waiting room patients. EHR data included: total number of visits, total number of unique patients, and numbers of unique patients with OUD, depression, or PTSD as well as more than one of these diagnoses. We obt... | PMC9881516 |
Statistical analyses | pain | Descriptive statistics from survey responses were calculated for age, gender, language preference, clinic attendance, and pain experience. Aggregate data over the 1-year period from the EHR records was obtained for each clinic and combined. These counts were divided by 26 for an average 2-week estimate for comparabilit... | PMC9881516 | |
Results | PMC9881516 | |||
Discussion | depression, OUD, co-occurring mental health disorders, PTSD | DISORDERS | Overall, in-person screening identified a nearly three-fold higher proportion of patients (2.4%) with probable OUD and co-occurring mental health disorders compared to the EHR (0.8%). We also identified a higher proportion of each condition separately (OUD, depression, and PTSD) with the survey. To our knowledge the pr... | PMC9881516 |
Conclusions | OUD, co-occurring mental health disorders | DISORDERS | This study helps quantify the potential extent of diagnostic and treatment service gaps for OUD and co-occurring mental health disorders in PC settings serving rural and socioeconomically disadvantaged patients in New Mexico. Rates of these disorders in these settings are generally higher than what is documented in the... | PMC9881516 |
Acknowledgements | opioid use disorder, co-occurring mental health disorders | The study is named Collaboration Leading to Addiction Treatment and Recovery from Other Stresses (CLARO Study). The CLARO Study Group includes the PIs and Co-Investigators, key staff (such as project directors and patient representatives), and key stakeholders. The authors appreciate the CLARO partnerships with First C... | PMC9881516 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.